The amplification of GNAS has been shown to be connected with resistance to cetuximab in patients with metastatic colorectal cancer (RAS w/t tumor) and also to be associated with poor progression-free survival in patients with ovarian cancer (68, 69). This evidence concerns the gene GNAS and metastatic colorectal cancer.